Roy Baynes, MB.Bch., M.Med., Ph.D., has served as a member of Nurix’s Medical Advisory Board since 2023. Dr. Baynes currently serves as Chief Medical Officer at Eikon Therapeutics, Inc. Dr. Baynes previously served as Chief Medical Officer at Merck & Co., where he was responsible for the development of the entire clinical portfolio in Merck Research Laboratories, and was the architect of the development strategy for dozens of important new medicines including pembrolizumab, a humanized monoclonal antibody used in cancer immunotherapy that treats some 17 different tumor types as well as two histology agnostic indications. Earlier in his career, Dr. Baynes served as Vice President of Global Development and head of the hematology/oncology development team at Amgen, Inc., as Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences, Inc., and as Professor of Medicine at University of Kansas Medical Center and Wayne State University in Detroit as well as holding the Charles Martin endowed chair of Cancer Research at Wayne State University. Dr. Baynes holds an MB.BCh. (Bachelor of Medicine and Surgery), an M.Med. (specialist registration in Internal Medicine), and a Ph.D. from the University of Witwatersrand.
'